<div class="article">
	<h3>Genzyme Unit's Initial Offering</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 05/04/90</li>
		</ul>
	</div>
	<p class="article-leader">FRAMINGHAM, Mass. -- IG Laboratories Inc., a unit of
Genzyme Corp., said it is offering 1,875,000 common shares in
its initial public offering at $7.50 a share. All of the
shares are being offered by the company.
   Upon completion of the offering, IG Laboratories will have
about 5.1 million shares outstanding and will be 56% owned by
Genzyme, a Boston-based maker of health-care products. IG
Labs provides genetic testing services to hospitals and other
health-care providers.</p>
	<div class="article-body"><p>Oppenheimer & Co. is the managing underwriter of the
offering.</p>
<p></p></div>
</div>
